GlassScriptPhysician profile
Imtiaz Hussain
NPI 1275610719
$7,156.85
in general payments reported to CMS, 2019-2025
42 companies · $1,863 in 2025
The $1,863 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $53.16 · 2021: $135 · 2022: $1,586 · 2023: $1,851 · 2024: $1,358 · 2025: $1,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,209 · Travel and Lodging: $668 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,209.26 |
| Travel and Lodging | $668.25 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $767.87 | 2020-2025 | Fasenra, Airsupra, Tezspire |
| Grifols USA, LLC | $731.27 | 2022-2025 | Prolastin-C Liquid |
| Insmed, INC. | $706.88 | 2023-2025 | Arikayce |
| Olympus Corporation of The Americas | $668.25 | 2025 | |
| Glaxosmithkline, LLC. | $570.30 | 2019-2025 | Trelegy Ellipta, Nucala |
| Actelion Pharmaceuticals US, INC. | $429.18 | 2022-2024 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.81 | 2022-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $322.71 | 2022-2025 | |
| Amgen INC. | $303.47 | 2022-2025 | Tezspire |
| United Therapeutics Corporation | $229.52 | 2022-2024 | Tyvaso, Orenitram |
| Regeneron Healthcare Solutions, INC. | $187.82 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $186.84 | 2021-2024 | Aralast, Glassia |
| Verona Pharma, INC. | $172.18 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $160.32 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Baxter Healthcare | $151.51 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $117.10 | 2022-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $100.86 | 2021-2024 | Zerbaxa, Recarbrio, Dificid |
| Erbe USA INC | $100.00 | 2025 | Erbecryo2 |
| Janssen Pharmaceuticals, INC | $86.13 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.88 | 2022-2023 | |
| Genentech USA, INC. | $73.43 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $68.70 | 2019 | |
| Mallinckrodt Hospital Products INC. | $58.97 | 2021-2025 | Acthar |
| Csl Behring | $55.13 | 2022-2024 | Kcentra |
| Philips North America LLC | $50.10 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Astellas Pharma US INC | $41.37 | 2023 | Cresemba |
| Pfizer INC. | $37.74 | 2023 | |
| Inogen, INC. | $35.67 | 2022-2023 | Inogen At Home Stationary Concentrator, Inogen One G3 Oxygen Concentrator |
| Chiesi USA, INC. | $33.39 | 2022-2023 | Kengreal, Cleviprex |
| Boston Scientific Corporation | $32.74 | 2024 | Ekosonic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.56 | 2019 | |
| Electromed, INC. | $28.00 | 2021-2023 | Smartvest |
| Nevro Corp. | $26.93 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $26.44 | 2022 | |
| Olympus America INC. | $26.44 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.42 | 2023 | Ultomiris |
| Siemens Medical Solutions USA, INC. | $18.65 | 2024 | Cios Spin |
| Tactile Systems Technology INC | $18.17 | 2025 | Nimbl, Flexitouch Plus |
| Abbvie INC. | $14.25 | 2022 | |
| Viatris Specialty LLC | $13.77 | 2025 | Yupelri |
| Ambu INC. | $13.00 | 2023 | |
| Lilly USA, LLC | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imtiaz Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.